Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
- PMID: 19635963
- PMCID: PMC2764164
- DOI: 10.1128/AAC.00208-09
Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
Abstract
Since the currently approved dose of daptomycin (6 mg/kg of body weight/day) has been associated with clinical failures and resistance development, higher doses for some difficult-to-treat infections are being proposed. We studied the efficacy of daptomycin at high doses (equivalent to 10 mg/kg/day in humans) and compared it to that of reference and alternative treatments in a model of foreign-body infection with methicillin (meticillin)-resistant Staphylococcus aureus. In vitro studies were conducted with bacteria in the log and stationary phases. For the in vivo model, therapy with daptomycin at 100 mg/kg/day, vancomycin at 50 mg/kg/12 h, rifampin (rifampicin) at 25 mg/kg/12 h, or linezolid at 35 mg/kg/12 h was administered for 7 days. Antibiotic efficacy was evaluated using either bacteria from tissue cage fluids or those attached to coverslips. We screened for the emergence of linezolid- and rifampin-resistant strains and analyzed the surviving population from the daptomycin-treated group. Only daptomycin was bactericidal in both the log- and stationary-phase studies. Daptomycin (decrease in the log number of CFU per milliliter of tissue cage fluid, 2.57) and rifampin (decrease, 2.6 log CFU/ml) were better (P < 0.05) than vancomycin (decrease, 1.1 log CFU/ml) and linezolid (decrease, 0.9 log CFU/ml) in the animal model. Rifampin-resistant strains appeared in 60% of cases, whereas no linezolid resistance emerged. No daptomycin-resistant subpopulations were detected at frequencies of 10(-7) or higher. In conclusion, daptomycin at high doses proved to be as effective as rifampin, and the two were the most active therapies for this experimental foreign-body infection. These high doses ensured a profile of safety from the development of resistance.
Figures
Similar articles
-
Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother. 2010 Dec;54(12):5251-6. doi: 10.1128/AAC.00226-10. Epub 2010 Oct 4. Antimicrob Agents Chemother. 2010. PMID: 20921321 Free PMC article.
-
Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother. 2012 Jul;56(7):3806-11. doi: 10.1128/AAC.00127-12. Epub 2012 May 14. Antimicrob Agents Chemother. 2012. PMID: 22585211 Free PMC article.
-
Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother. 2013 Jan;57(1):606-10. doi: 10.1128/AAC.01570-12. Epub 2012 Oct 22. Antimicrob Agents Chemother. 2013. PMID: 23089756 Free PMC article.
-
Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL.Ann Pharmacother. 2013 Dec;47(12):1654-65. doi: 10.1177/1060028013508272. Epub 2013 Nov 1. Ann Pharmacother. 2013. PMID: 24259618 Review.
-
Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.Infect Dis Clin North Am. 2020 Dec;34(4):849-861. doi: 10.1016/j.idc.2020.04.003. Epub 2020 Sep 30. Infect Dis Clin North Am. 2020. PMID: 33011050 Review.
Cited by
-
In Vivo Effects of Cefazolin, Daptomycin, and Nafcillin in Experimental Endocarditis with a Methicillin-Susceptible Staphylococcus aureus Strain Showing an Inoculum Effect against Cefazolin.Antimicrob Agents Chemother. 2013 Sep;57(9):4276-4281. doi: 10.1128/AAC.00856-13. Epub 2013 Jun 24. Antimicrob Agents Chemother. 2013. PMID: 23796934 Free PMC article.
-
Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.Microbiol Mol Biol Rev. 2014 Sep;78(3):510-43. doi: 10.1128/MMBR.00013-14. Microbiol Mol Biol Rev. 2014. PMID: 25184564 Free PMC article. Review.
-
Foreign Body Infection Models to Study Host-Pathogen Response and Antimicrobial Tolerance of Bacterial Biofilm.Antibiotics (Basel). 2014 Aug 21;3(3):378-97. doi: 10.3390/antibiotics3030378. Antibiotics (Basel). 2014. PMID: 27025752 Free PMC article. Review.
-
Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.Antimicrob Agents Chemother. 2012 Oct;56(10):5296-302. doi: 10.1128/AAC.00797-12. Epub 2012 Aug 6. Antimicrob Agents Chemother. 2012. PMID: 22869564 Free PMC article.
-
Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections.Antimicrob Agents Chemother. 2013 Jul;57(7):3450-2. doi: 10.1128/AAC.00325-12. Epub 2013 May 6. Antimicrob Agents Chemother. 2013. PMID: 23650174 Free PMC article.
References
-
- Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, and B. I. Eisenstein. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681. - PubMed
-
- Bassetti, M., F. Vitale, G. Melica, E. Righi, B. A. Di, L. Molfetta, F. Pipino, M. Cruciani, and D. Bassetti. 2005. Linezolid in the treatment of Gram-positive prosthetic joint infections. J. Antimicrob. Chemother. 55:387-390. - PubMed
-
- Berger-Bachi, B., A. Strassle, and F. H. Kayser. 1986. Characterization of an isogenic set of methicillin-resistant and susceptible mutants of Staphylococcus aureus. Eur. J. Clin. Microbiol. 5:697-701. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical